Inovio Pharmaceuticals Inc (INO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $262.23M
Last updated: Nov 17, 2026 at 4:43 PM ET
Inovio Pharmaceuticals Inc (INO) Stock Chart
Inovio Pharmaceuticals (INO) has a latest price of $1.63 on Nov 17, 2026, 40.1% below its 52-week high of $2.72. Its price fell 20.5% over the past 12 months. The month-end price fell 99.2% over the 10 years through Oct 2026, a compound annual decline of 38.5%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $323.53 in Jun 2020 and its lowest $0.60 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart INO with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for INO.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 25.4%, and over 6 months it rose 33.6%. The month-end price fell 86.2% over the 3 years through Oct 2026, a compound annual decline of 48.4%.
| Period | Change |
|---|---|
| 1 month | +63.0% |
| 3 months | +25.4% |
| 6 months | +33.6% |
| 12 months | -20.5% |
| 12 months, with dividends | -20.5% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -86.2% | -48.4% |
| 5 years | -99.3% | -62.9% |
| 10 years | -99.2% | -38.5% |
Price by Year
Its best calendar year was 2020, when the price rose 168.2%, and its weakest was 2024, when it fell 70.1%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $0.60 | -65.4% |
| 2025 | $1.74 | -4.9% |
| 2024 | $1.83 | -70.1% |
| 2023 | $6.12 | -67.3% |
| 2022 | $18.73 | -68.7% |
| 2021 | $59.90 | -43.6% |
| 2020 | $106.24 | +168.2% |
| 2019 | $39.62 | -17.5% |
| 2018 | $48.02 | -3.1% |
| 2017 | $49.58 | -40.5% |
Trading Range
The price is 37.2% above its 50-day average of $1.19 and 29.3% above its 200-day average of $1.26.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.63 | |
| 52-week high | $2.72 | -40.1% |
| 52-week low | $0.56 | +191.1% |
| 50-day average | $1.19 | +37.2% |
| 200-day average | $1.26 | +29.3% |
Price Risk
Over 3 years, its largest fall from a peak was 95.7%.
| Measure | Value |
|---|---|
| 1-year beta | 0.56 |
| Largest fall, 1 year | -76.8% |
| Largest fall, 3 years | -95.7% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About INO
What is INO's 1-year price change?
Inovio Pharmaceuticals's price fell 20.5% over the past 12 months. With dividends included, the 12-month total return was -20.5%.
What is INO's 5-year price change?
Inovio Pharmaceuticals's month-end price fell 99.3% over the 5 years through Oct 2026, a compound annual decline of 62.9%. These figures leave out dividends.
What is INO's 52-week high and low?
Inovio Pharmaceuticals's 52-week high is $2.72 and its 52-week low is $0.56. Its latest price of $1.63 on Nov 17, 2026 is 40.1% below the high.
What is INO's beta?
Inovio Pharmaceuticals's 1-year beta against the S&P 500 is 0.56, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 76.8%.
Is the INO chart free?
Yes. Advanced Charting for INO is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
INO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors